CD22 positive
|
B Acute Lymphoblastic Leukemia
|
CD22 positive
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
CD22 positive
|
Lymphoma
|
CD22 positive
|
Lymphoma
|
moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria
|
moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria
|